Echoiq Limited · ASX:EIQ
Echoiq — Investor Presentation (October 2023)
23 slides from Echoiq's investor presentation, Oct 16, 2023
Slide 1: Company Presentation 16 October 2023
Company Presentation 16 October 2023
Slide 2: Disclaimer and forward-looking statements
Disclaimer and forward-looking statements This presentation has been prepared by ECHOIQ LIMITED “EIQ”. This document jurisdiction of the United States, and may not be offered or sold in the United contains background information about EIQ current at the date of this States to any person without bein
Slide 3: Corporate Snapshot
Corporate Snapshot SHAREHOLDER BREAKDOWN 494,404,375 Shares on issue 47% Board of Directors 53% Other & Top 20 Shareholders A$0.20 BOARD OF DIRECTORS Share Price (13.10.2023) Jul '22 Oct'23 A$98.9 FIRST REVENUES ACHIEVED MAY 2023 Market Capitalisation Andew Grover Steven Formica Executive Chair Non-
Slide 4: Using AI and data science to improve detection of structural heart disease
uses the power of artifical intelligence and data science to improve detection of structural heart disease.
Slide 5: The Problem
The Problem 30% 1 in 2 2 yrs 2 3 1 of all deaths worldwide people with heart valve mortality rate for certain attributed to disease don't know forms of untreated cardiovascular disease they've got it structural heart disease structural heart disease is common it is becoming more prevalent left untre
Slide 6: Diagnosing Structural Heart Disease
Diagnosing Stuctural Heart Disease TRANS-THORACIC ECHOCARDIOGRAM > Most widely used tool in the diagnosis of structural heart disease, with more than 30M “echo’s” performed in the US each year alone > Images of the heart captured using ultrasound (soundwaves), with scanning equipment easily accessib
Slide 7: EchoSolv identified 100% of severe aortic stenosis patients
In a recent clinical study, Echo IQ’s EchoSolv technology was shown TM to accurately identify 100% of patients with severe aortic stenosis, a leading form of structural heart disease. This represents a 72% improvement versus human-only diagnosis. Refer to ASX announcement dated 19 April 2023
Slide 8: Scientifically-Proven AI
SCIENTIFICALLY-PROVEN AI For enhancing diagnosis of structural heart disease TM EchoSolv removes the labour intensiveness, user-dependency and unconscious bias in diagnosis which can lead to greater accuracy compared to traditional methods. Patient triage Real-time Rapid AI View Guideline on-the-go
Slide 9: Current Solution Set
Available now Current Solution Set Aortic Stenosis Severe AS Guidelines LEADING CAUSES OF HEART VALVE DISEASE Severe AS AI Phenotype* Severe Aortic Stenosis occurs when the aortic valve stiffens and fails to open and close properly. It has a 2-year mortality rate of 50% when left 5 untreated. Timely
Slide 10: Product Pipeline
Available now Available Nov 23 - Jan 24 Product Pipeline Echo IQ has a clear near-term roadmap for Aortic Stenosis whole-of-structural-heart solutions. Severe AS Guidelines Severe AS AI Phenotype Diastolic Dysfunction Guidelines Tool (Nov’23) 7 Left Atrial Volume Affects 20-30% of adult population I
Slide 11: Our Competitive Moat
BACKED BY CLINICALLY Our CARDIAC BIG DATA > Exclusive AI access to National VALIDATED > US study demonstrated 100% Echo Database of Australia accuracy in detection of AHA Competitive (NEDA) echo measurement data (world’s largest) defined severe aortic stenosis > Australian study showed MOAT > Mortal
Slide 12: Proven clinical effectiveness
Proven clinical effectiveness W ST VINCENTS EchoSolv™ identified 100% of the patients with guideline-defined severe aortic stenosis, equal to ~5% of the study population. EchoSolv™ identified an additional cohort, similar in size, at high risk of mortality. 3 in 4 of the EchoSolv™ identified cases w
Slide 13: Rapid progress since acquisition
Rapid progress since acquisition Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 TM FDA Strategy Advisory Board EchoSolv Launch US Team Established Maiden Revenues New EchoSolv for MR + Strategy defined + Leading international + Platform for AS + President + AUS Private Hospital + New solution intro
Slide 14: Commercialisation Strategy
Commercialisation Strategy CLINICAL VALIDATION COMMERCIAL SAAS & REGULATORY PILOTS AGREEMENTS Clinical studies at St. Vincent’s Pilot with Advara HeartCare, Australia’s Agreements in place in Australian Hospitals (AU) and Beth Israel leading provider of cardiology services cardiology and hospital se
Slide 15: SaaS Revenue Model
SaaS Revenue Model Pay-as-you-go Enterprise Per Study Fixed Monthly Fee Ideal for Echo labs and clinics with lower volumes Unlimited assessments with predictable pricing Severe Aortic Stenosis Guidelines Detection Severe Aortic Stenosis Guidelines Detection Severe Aortic Stenosis AI Phenotype Severe
Slide 16: Rapid Market Development
Rapid Market Development MARKET USAGE MODE REVENUE MODEL IT S N E S A D FE TE A SA U SC A A -A E T LI ST LY M C TY R A JE TI PE TH R ED LI L- ST O A N E EA IT PR U U O FE N A Q R M U Hospital Cardiology Practice PARTNER TYPE PACS/Reporting Distributor Valve Manufacturer Hardware Scanning Contracted
Slide 17: Structural Heart Solutions: The Commercial View
Structural Heart Solutions The Commercial View Conditions Treated with Conditions Treated with Drug Mechanical Devices (eg. Valves) and Pharmaceutical Therapies Aortic Stenosis Diastolic Dysfunction Mitral Stenosis Heart Failure Mitral Regurgitation Pulmonary Hypertension 1. Identify more patients 1
Slide 18: Case Study: Potential Impact in Hospital Setting
Case Study: Potential Impact in Hospital Setting Impact AI + Review Mode Human-Only Automation Number of EchoCardiograms Assessed 9189 9189 Number of Severe Aortic 218 Stenosis cases detected 376 + 72% Hospital income from respective valve replacements * US$6.98M US$9.84M + 41% *Extrapolated figures
Slide 19: Scientific Advisory Board
Scientific Advisory Board > Comprises a team of globally recognised Prof. Huon H. Gray Partho Sengupta James Thomas experts in cardiovascular medicine, CBE MD MD MBBS FACC FASE MD FACC FASE FESC Former National Clinical Director Henry Rutgers Professor of Former President Am. Society of echocardiogr
Slide 20: 510k FDA clearance pathway
510k FDA clearance pathway Securing FDA clearance in US market Allows cardiologists to pursue undiagnosed patients and tap revenue becomes a material revenue accelerator from insurance and public health rebate channels (similar to Medicare). Q4 2022 Q1 2023 Q2/3 2023 Q4 2023 Q1 2024 Pre-submission R
Slide 21: Investment Highlights
Investment Highlights Echo IQ is now revenue generating with paying customers in 1 professional healthcare segments Strong sales pipeline in the US and Australia with new contracts 2 imminent TM EchoSolv advances from single disease solution to complete 3 structural heart decision support tool for c
Slide 22: References
References 1. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) 2. https://www.baker.edu.au/-/media/documents/impact/baker-institute_our-hidden-ageing-whitepaper.pdf?la=en 3. https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Tools-and-Practice-Suppor
Slide 23: Contacts
Contacts: Andrew Grover, Executive Chair andrew.grover@echoiq.ai Deon Strydom, Chief Commercial Officer deon.strydom@echoiq.ai